pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›SRX-25
drug
save

SRX-25

Preclinicalupdated 6mo ago
by Nexalis Therapeutics Ltd
Preclinical
community read0 votes

🐶 often sniffed alongside

top 8
  • drugesketamine hydrochloride35 co-mentions · 18 sources
  • tagApproval34 co-mentions · 17 sources
  • drugesketamine20 co-mentions · 20 sources
  • tagOncology2 co-mentions · 1 sources
  • tagPain2 co-mentions · 2 sources
  • companyFirst Affiliated Hospital of Anhui Medical University1 co-mentions · 1 sources
  • companyChiral Biotech Pharma Pty Ltd1 co-mentions · 1 sources
  • companyHuzhou Maternity and Child Care Hospital1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying SRX-25

  • phase3A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depressionrecruitingn=348
  • phase3A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorderrecruitingn=258
  • phase4A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depressionrecruitingn=47
  • phase4A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatmentcompletedn=183
  • —Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)approved for marketing
  • phase3A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depressioncompletedn=236
  • phase2A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depressioncompletedn=30
  • phase3A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depressioncompletedn=719

News(10)

  • HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
    Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.
    biospace · 5d ago
  • ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veterans
    The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).
    fiercebiotech · 6d ago
  • Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’
    The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”
    stat · 1mo ago
  • Deep dive: Psychedelics back on FDA’s doorstep
    BioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.
    biospace · 2mo ago
  • Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
    Safety and access were top of mind at Monday’s public hearing exploring the regulation of psychedelic therapies. "The medicine opens the door,” NeuroAlchemy co-founder Michaela Vogt said during the…
    biospace · 2mo ago
  • Psychedelic therapies ride wave of public favor into FDA hearing
    Heading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…
    biospace · 2mo ago
  • Psychedelics on the cusp of market breakthrough as clinical, policy support grow
    While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.
    biospace · 3mo ago
  • Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
    Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…
    biospace · 4mo ago
  • ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
    After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
    fiercebiotech · 4mo ago
  • Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
    With the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry.
    biospace · 4mo ago
view all news mentions →
generic
esketamine
indication
Treatment Resistant Depression
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?